Plastic and reconstructive surgery · 2025
Alveolar Bone Grafting: Outcomes Utilizing Synthetic HA/TCP and rhBMP-2 versus Autologous Graft Types.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kahan Riley H, Palmer Skyler K, Garoosi Kassra, Gomez Diego A, Khechoyan David Y, French Brooke, Lowe Kristen, Nguyen Phuong D
Аннотация
BACKGROUND: Alveolar ridge defects associated with cleft lip and palate are typically repaired using alveolar bone grafting (ABG), with autologous grafting as the standard despite donor-site morbidity. This study investigated outcomes of using hydroxyapatite/ß-tricalcium phosphate (HA/TCP) as a synthetic graft alternative.
METHODS: A retrospective cohort study identified 118 patients who underwent ABG by means of CPT codes and were divided into 3 groups: autologous iliac crest bone graft (ICBG) ( n = 37), ICBG plus recombinant human bone morphogenetic protein-2 (rhBMP-2) ( n = 65), and 15% HA/TCP plus rhBMP-2 ( n = 16). Primary outcomes included need for regrafting and percentage graft take, assessed by means of cone beam computed tomographic imaging. Secondary outcomes included complication rates (swelling, wound dehiscence, surgical-site infection) and perioperative data (surgery length, hospital stay).
RESULTS: Patients who received HA/TCP plus rhBMP-2 experienced similar rates of need for regrafting to the other groups. The median percentage graft take was higher for HA/TCP plus rhBMP-2 (68.0%; interquartile range [IQR], 45.9% to 93.1%) compared with ICBG (25.1%; IQR, 5.2% to 43.5%; Z = 3.16; P = 0.002) and ICBG plus rhBMP-2 (44.2%; IQR, 24.5% to 63.1%; Z = 2.19; P = 0.028). Complication rates were similar across groups (dehiscence, P = 0.319; surgical-site infection, P = 0.357), except for a higher rate of postsurgical facial swelling for HA/TCP plus rhBMP-2 compared with ICBG (OR, 6.8; 95% CI, 1.44 to 32.00; P = 0.0157).
CONCLUSION: HA/TCP plus rhBMP-2 is a viable alternative to ABG, showing comparable success to ICBG and ICBG plus rhBMP-2, with superior percentage graft take and no increased complication risk, aside from increased postsurgical facial swelling compared with ICBG.
METHODS: A retrospective cohort study identified 118 patients who underwent ABG by means of CPT codes and were divided into 3 groups: autologous iliac crest bone graft (ICBG) ( n = 37), ICBG plus recombinant human bone morphogenetic protein-2 (rhBMP-2) ( n = 65), and 15% HA/TCP plus rhBMP-2 ( n = 16). Primary outcomes included need for regrafting and percentage graft take, assessed by means of cone beam computed tomographic imaging. Secondary outcomes included complication rates (swelling, wound dehiscence, surgical-site infection) and perioperative data (surgery length, hospital stay).
RESULTS: Patients who received HA/TCP plus rhBMP-2 experienced similar rates of need for regrafting to the other groups. The median percentage graft take was higher for HA/TCP plus rhBMP-2 (68.0%; interquartile range [IQR], 45.9% to 93.1%) compared with ICBG (25.1%; IQR, 5.2% to 43.5%; Z = 3.16; P = 0.002) and ICBG plus rhBMP-2 (44.2%; IQR, 24.5% to 63.1%; Z = 2.19; P = 0.028). Complication rates were similar across groups (dehiscence, P = 0.319; surgical-site infection, P = 0.357), except for a higher rate of postsurgical facial swelling for HA/TCP plus rhBMP-2 compared with ICBG (OR, 6.8; 95% CI, 1.44 to 32.00; P = 0.0157).
CONCLUSION: HA/TCP plus rhBMP-2 is a viable alternative to ABG, showing comparable success to ICBG and ICBG plus rhBMP-2, with superior percentage graft take and no increased complication risk, aside from increased postsurgical facial swelling compared with ICBG.